公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2016 年第一季度报告 二○一六年四月二十六日 | 一、重要提示 | 3 | | --- | --- | | 二、公司主要财务数据和股东变化 | 3 | | 三、重要事项 | 5 | | 四、附录 | 10 | 广誉远中药股份有限公司 2016 年第一季度报告 一、重要提示 二、公司主要财务数据和股东变化 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上 | | | --- | --- | --- | --- | --- | | | | | 年度末增减(%) | | | 总资产 | 1,083,421,562.69 | 1,066,436,413.17 | | 1.59 | | 归属于上市公司股东的净资产 | 723,137,221.54 | 715,044,652.28 | | 1.13 | | | 年初至报告期末 | 上年初至 上年报告期末 | 比上年同期 增减(%) | | | 经营活动产生的现金流量净额 | -45,997,785.24 | -2,434,119.68 | | -1,7 ...

Financial Performance - The company achieved a net profit attributable to shareholders of 2.03 million RMB in 2015, a decrease of 94.46% compared to 36.65 million RMB in 2014[5]. - Operating revenue for 2015 was 428.44 million RMB, representing a year-on-year increase of 20.97% from 354.15 million RMB in 2014[23]. - The net cash flow from operating activities was -60.01 million RMB, a decline of 33.06% compared to -45.10 million RMB in 2014[23]. - The total assets at the end of 2015 reached 1.07 billion RMB, an increase of 130.73% from 462.21 million RMB at the end of 2014[23]. - The company's net assets attributable to shareholders increased by 750.14% to 715.04 million RMB at the end of 2015, compared to 84.11 million RMB at the end of 2014[23]. - Basic earnings per share decreased by 93.33% to CNY 0.01 in 2015 from CNY 0.15 in 2014[25]. - Diluted earnings per share also fell by 93.33% to CNY 0.01 in 2015 compared to CNY 0.15 in 2014[25]. - The weighted average return on equity dropped by 55.12 percentage points to 0.59% in 2015 from 55.71% in 2014[25]. - The company reported a net profit for the year of CNY 2.03 million, a significant decrease of 94.46% compared to the previous year[55]. Cash Flow and Investments - The company reported a net cash flow from operating activities of -CNY 48,984,687.15 in Q3 2015, indicating cash flow challenges[27]. - The company raised 621.37 million yuan through a private placement, resulting in a 1277.62% increase in cash and cash equivalents compared to the previous year[40]. - The company invested 62.17 million yuan in construction projects to expand production capacity, marking a 3887.22% increase year-on-year[40]. - The company raised CNY 639.20 million through a private placement of 34 million shares to enhance capital strength and support future business development[48]. - The company’s cash flow from financing activities increased by 743.41% to CNY 68,982,630.00, primarily due to a successful private placement raising CNY 62,322,000[67]. Market and Sales Performance - The company achieved a sales revenue of 428.44 million yuan, an increase of 74.28 million yuan, representing a growth rate of 20.97% year-on-year[37]. - Traditional Chinese medicine sales revenue increased by 27.44%, while the comparable growth rate for premium Chinese medicine reached 32.88%[38]. - The company's pharmaceutical commercial revenue accounted for 13.97% of total operating income during the reporting period[37]. - The company’s sales revenue completion rate for the year was 77.05%, indicating challenges in meeting initial targets due to market conditions[51]. - The company’s marketing strategy focuses on three pillars: traditional Chinese medicine, premium Chinese medicine, and health wine, aiming for comprehensive sales growth[51]. Research and Development - The company is actively engaged in research and development of new products to expand its market presence[35]. - Research and development expenses rose by 120.21% to CNY 2.81 million, indicating a focus on innovation and product development[53]. - The company plans to launch new products in 2016, including "Guan Lu Xiao Ke Capsule" and "Liang Wei Di Huang Capsule" using new technology processes[100]. - The company has five ongoing R&D projects focused on product process research and pharmacological studies[98]. - The company plans to establish a research and development center to enhance product development and modern clinical research capabilities[92]. Regulatory and Market Risks - The company faces risks from intensified market competition and regulatory changes in the pharmaceutical industry, which may impact future profitability[9]. - The company is preparing for the impact of new healthcare policies, including the expansion of urban residents' basic medical insurance and cost control measures[86]. - The company faces risks from industry policies, market competition, and raw material price fluctuations, which could impact its operational development[132][133]. Corporate Governance and Compliance - The company has established a cash dividend policy that aims to distribute at least 10% of the annual distributable profit in cash, subject to certain conditions[141]. - The company has not reported any significant litigation or arbitration matters that remain unresolved[150]. - The company has maintained compliance with all its financial commitments and obligations during the reporting period[147]. - The company has established a mechanism for evaluating marketing activities and tracking analysis to effectively control sales expenses[116]. Shareholder and Equity Information - The company issued 34 million A-shares at a price of 18.80 RMB per share, approved by the China Securities Regulatory Commission, increasing total shares from 243,808,438 to 277,808,438[188]. - The largest shareholder, Xi'an Dongsheng Group Co., Ltd., holds 54,048,265 shares, representing 19.46% of total shares, with all shares pledged[193]. - The company has a total of 34 million restricted shares released on July 28, 2018, due to non-public issuance[186]. - The company has not identified any related party relationships among its major shareholders, indicating a diverse ownership structure[194]. Environmental and Social Responsibility - The company is committed to adhering to stricter environmental protection laws, which may increase operational costs but is essential for compliance[85]. - Environmental protection expenses for 2015 amounted to approximately 1.06 million CNY, with all pollutant emissions meeting regulatory standards[177]. - The company has fully implemented clean production practices and passed the environmental protection audit in March 2014[178].

广誉远中药股份有限公司 2015 年第三季度报告 二○一五年十月三十一日 | 一、重要提示 | | 3 | | --- | --- | --- | | 二、公司主要财务数据和股东变化 | | 3 | | 三、重要事项 | | 6 | | 四、附录 | | 10 | 广誉远中药股份有限公司 2015 年第三季度报告 一、重要提示 公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2015 年第三季度报告 非经常性损益项目和金额 √适用 □不适用 1.4 本公司第三季度报告未经审计。 二、公司主要财务数据和股东变化 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上 | | --- | --- | --- | --- | | | | | 年度末增减(%) | | 总资产 | 1,124,387,347.93 | 462,210,831.14 | 143.26 | | 归属于上市公司股东的净资产 | 706,636,203.62 | 84,109,134.42 | 740.14 | | | 年初至报告期末 | 上年初至上年报告 | 比上年同期 | | | （1-9 月） | ...

Financial Performance - The company's operating revenue for the first half of 2015 was CNY 203,319,228.23, representing a 25.45% increase compared to CNY 162,070,403.49 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 79.52% to CNY 771,739.35 from CNY 3,767,773.23 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY -8,019,106.79, a decline of 465.96% compared to CNY 2,191,246.93 in the previous year[19]. - Basic earnings per share decreased by 85.00% to CNY 0.003 from CNY 0.02 in the same period last year[20]. - The weighted average return on net assets dropped by 6.74 percentage points to 0.90% from 7.64% year-on-year[20]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 465.96% to -8.02 million yuan, primarily due to increased sales costs and expenses[33]. - The net profit for the current period was ¥5,198,565.95, down from ¥10,511,856.05, a decrease of around 50.5%[89]. - The total profit for the current period was ¥8,094,057.21, down from ¥11,945,941.09, a decrease of approximately 32.4%[88]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 37.39%, reaching CNY -5,017,765.44, compared to CNY -8,014,956.46 in the same period last year[19]. - Cash flow from operating activities showed a net outflow of ¥5,017,765.44, improving from a net outflow of ¥8,014,956.46 in the previous period[95]. - The total cash inflow from investment activities was 6,906,000.00 RMB, down from 63,680,000.00 RMB in the previous period, representing a decline of about 89.1%[96]. - The net cash flow from financing activities was -1,238,011.03 RMB, an improvement from -76,171,172.96 RMB year-over-year, reflecting a significant reduction in cash outflow[99]. - The total cash and cash equivalents at the end of the period stood at 29,161,192.56 RMB, compared to 6,283,849.65 RMB at the end of the previous period, marking an increase of approximately 364.5%[96]. Assets and Liabilities - The total assets of the company increased by 11.45% to CNY 515,153,647.01 from CNY 462,210,831.14 at the end of the previous year[19]. - Total current assets increased to ¥430,944,862.31 from ¥375,955,021.45, representing a growth of approximately 14.6%[81]. - Total liabilities increased to ¥407,704,293.68 from ¥376,561,727.25, reflecting a rise of about 8.4%[82]. - The company's long-term equity investment balance was ¥13,937,400, a decrease of 8.84% from the previous year[39]. Operational Efficiency - Operating revenue increased by 25.45% to 203.32 million yuan, while operating costs rose by 63.56% to 58.79 million yuan[28]. - Sales expenses increased by 43.35% to 105.02 million yuan, driven by enhanced brand promotion and sales network construction[28]. - Research and development expenses surged by 3,742.99% to 1.03 million yuan, reflecting investments in new product development[30]. - Investment income rose significantly by 375.28% to 7.28 million yuan, attributed to the transfer of equity stakes in certain subsidiaries[30]. Strategic Initiatives - The company continues to focus on the "full industry chain to create high-quality traditional Chinese medicine" strategy, enhancing operational efficiency through innovative marketing[24]. - The company aims to strengthen its market presence by focusing on the development of core products in both traditional and premium Chinese medicine sectors[25]. - The company plans to enhance its capital strength through a non-public stock issuance, raising a total of 63.92 million yuan by issuing 34 million shares at 18.80 yuan each[26]. - The company has committed to invest RMB 460 million in Ankang Guoyuan Pharmaceutical Co., Ltd. and RMB 60 million in Beijing Xinglin Yuyuan Technology Co., Ltd.[60]. Shareholder and Governance - The company has revised its governance structure to protect the rights of shareholders and ensure compliance with regulations[63]. - The company has updated its shareholder meeting rules to enhance the protection of shareholder rights and interests[64]. - As of the end of the reporting period, the total number of shareholders was 13,670[69]. - The largest shareholder, Xi'an Dongsheng Group Co., Ltd., holds 54,048,265 shares, accounting for 22.17% of the total shares, with all shares pledged[71]. Market and Product Development - The company operates in the pharmaceutical industry, focusing on the production and sale of traditional Chinese medicine and related products[117]. - The company’s main products include traditional Chinese medicines such as Gui Ling Ji and Ding Kun Dan, which are key to its market strategy[117]. - The company provided a positive outlook for the next quarter, projecting a revenue growth of 25% year-over-year, driven by new product launches and market expansion strategies[126]. - New product development efforts are focused on traditional Chinese medicine, with an investment of 100 million RMB allocated for R&D in the upcoming year[126]. Financial Reporting and Compliance - The company adheres to the enterprise accounting standards, ensuring that its financial reports accurately reflect its financial status and performance[122]. - The accounting period for the company is aligned with the calendar year, running from January 1 to December 31[123]. - The company has not reported any new capital contributions from shareholders during this period[109]. - The company has not made any adjustments for prior period errors or changes in accounting policies during this reporting period[108].

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2014 年年度报告 二○一五年三月十日 广誉远中药股份有限公司 2014 年年度报告 重要提示 经利安达会计师事务所（特殊普通合伙）审计确认，公司2014年度实现归属于母 公司所有者的净利润3664.64万元，年末累计未分配利润为-62548.21万元。由于累计 未分配利润为负，不具备分配条件，因此本年度不进行现金利润分配，也不进行资本 公积金转增股本，本年度收益全部用来弥补以前年度亏损。 六、前瞻性陈述的风险声明 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质 承诺，敬请投资者注意投资风险。 否 2 / 176 一、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、公司全体董事出席董事会会议。 三、利安达会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报 告。 四、公司负责人张斌、主管会计工作负责人傅淑红 及会计机构负责人（会计主管人 员）侯宽余声明：保证年度报告中财务报告的真实、准确、完整。 五 ...

二○一五年四月二十七日 公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2015 年第一季度报告 | | | | 一、重要提示 3 | | --- | | 二、公司主要财务数据和股东变化 3 | | 三、重要事项 6 | | 四、附录 9 | 广誉远中药股份有限公司 2015 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张斌、主管会计工作负责人傅淑红及会计机构负责人（会计主管人员） 侯宽余保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司主要财务数据和股东变化 2.1 主要财务数据 3 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比 上年度末增减（%） 总资产 489,765,200.97 462,210,831.14 5.96 归属于上市公司股东的净资产 82,943,926.07 84,109,134.43 -1.39 ...

广誉远中药股份有限公司 GuangYuYuan Chinese Herbal Medicine Co., Ltd. 2014 年第三季度报告 二〇一四年十月二十九日 | 目录 | | --- | | 一、 | 重要提示 2 | | --- | --- | | 二、 | 公司主要财务数据和股东变化 2 | | 三、 | 重要事项 4 | | 四、 | 附录 10 | 广誉远中药股份有限公司 2014 年第三季度报告 一、 重要提示 二、 公司主要财务数据和股东变化 2.1 主要财务数据 | 单位：元 币种：人民币 | | --- | | | 本报告期末 | 上年度末 | 本报告期末比 上年度末增减(%) | | | --- | --- | --- | --- | --- | | 总资产 | 602,914,649.46 | 526,129,197.90 | | 14.59 | | 归属于上市公司股东的净资产 | 49,333,986.24 | 47,462,751.34 | | 3.94 | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | | （1-9 月） | （1-9 ...

广誉远中药股份有限公司 600771 2014 年半年度报告 二○一四年八月二日 广誉远中药股份有限公司 2014 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律 责任。 二、公司全体董事出席董事会会议。 三、公司半年度财务报告未经审计。 四、公司负责人董事长张斌、主管会计工作负责人财务总监傅淑红及会计机构负责 人（会计主管人员）财务经理侯宽余声明：保证本半年度报告中财务报告的真实、准确、 完整。 五、本半年度报告中所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投 资者的实质承诺，敬请投资者注意投资风险。 六、是否存在被控股股东及其关联方非经营性占用资金情况？否 七、是否存在违反规定决策程序对外提供担保的情况？否 1 广誉远中药股份有限公司 2014 年半年度报告 目 录 | 第一节 | 释义 | 3 | | --- | --- | --- | | 第二节 | 公司简介 | 4 | | 第三节 | 会计数据和财务指标摘要 | 5 | | 第四节 | 董事会报告 | 6 | | ...

广誉远中药股份有限公司 GuangYuYuan Chinese Herbal Medicine Co., Ltd. 广誉远 2014 年第一季度报告 一、重要提示 1.1 本公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、 准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会会议审议季度报告。 1.3 公司第一季度财务报告未经审计。 2014 年第一季度报告 1.4 | 公司负责人姓名 | 董事长张斌 | | --- | --- | | 主管会计工作负责人姓名 | 财务总监傅淑红 | | 会计机构负责人（会计主管人员）姓名 | 财务经理侯宽余 | 二○一四年四月二十五日 公司负责人董事长张斌、主管会计工作负责人财务总监傅淑红及会计机构负责人 （会计主管人员）财务经理侯宽余保证季度报告中财务报表的真实、准确、完整。 | 截止报告期末股东总数 | | | 17,278 | | | | --- | --- | --- | --- | --- | --- | | 前十名股东持股情况 | | | | | | | 持股比 股东名称 | 股东性质 | ...

(R) 养生精品中药 始于1541 2013 年度报告 广誉远中药股份有限公司 China Time-honored Brand 中国非物质文化遗产 gible Cultural Heritage 国家保密配方 重要脂示 公司董事会、监事会及董事、监事、高级管理人员保证年度报告 内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 利安达会计师事务所（特殊普通合伙）为本公司出具了标准无保 ။ 留意见的审计报告。 四、 公司负责人董事长张斌、主管会计工作负责人财务总监傅淑红及 会计机构负责人（会计主管人员）财务经理侯贲余声明：保证年 度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案:经 利安达会计师事务所（特殊普通合伙）审计确认，公司2013年 度亏损1956,40万元,故本年度不进行现金利润分配,也不进 行资本公积金转增股本。 六、 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司 对投资者的实质承诺，敬请投资者注意投资风险。 七、 本报告期公司不存在被控股股东及其关联方非经营性 ...